MedWatch

Pharma giant on new Nordic headquarters: This is why we chose Copenhagen

Japan's second largest pharmaceutical company wants to establish itself in the North, where an unknown number of employees based in Copenhagen will spearhead the company's Nordic advance.

Closeness to universities such as Karolinska Instituttet in Sweden and Copenhagen University (picture) have been contributing factors in attracting the global company Daiichi Sankyo to Copenhagen. | Foto: Københavns Universitet/PR

Copenhagen's strong life science environment and central placement in the North was the deciding factor that made the global pharmaceutical company Daiichi Sankyo choose the Danish capital as its base for its advancement in the Nordic countries, explains Patrik Grandits, Managing Director and Head of Commercial Operations for Oncology at Daiichi Sankyo Europe to MedWatch.

He emphasizes the short distance to leading hospitals and universities such as Rigshospitalet in Copenhagen and Karolinska Instituttet in Sweden as a strenght.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier